R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo

Phase 3Completed
1 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemodialysis Patients

Conditions

Hemodialysis Patients

Trial Timeline

Jun 1, 2007 → Aug 1, 2008

About R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo

R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo is a phase 3 stage product being developed by Chugai Pharmaceutical for Hemodialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT00491868. Target conditions include Hemodialysis Patients.

What happened to similar drugs?

2 of 15 similar drugs in Hemodialysis Patients were approved

Approved (2) Terminated (0) Active (13)
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
🔄roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
🔄roxadustatAstellas PharmaPhase 3
DoravirineMerckApproved
🔄PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00491868Phase 3Completed

Competing Products

20 competing products in Hemodialysis Patients

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
ASP7991Astellas PharmaPhase 1
29
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
ASP1585Astellas PharmaPhase 2
35
Kiklin capsulesAstellas PharmaPre-clinical
26
DoravirineMerckApproved
43
BPS804 + PlaceboNovartisPhase 2
27
PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3
40
PA21 + PA21 + PA21 + PA21 + PlaceboKissei PharmaceuticalPhase 2
35
PA21Kissei PharmaceuticalPhase 3
40
PA21Kissei PharmaceuticalPhase 3
40
[¹⁴C]EtelcalcetideAmgenPhase 1
29
Epoetin HospiraPfizerPhase 3
40
Epoetin HospiraPfizerPhase 3
40
sodium thiosulfateSanofiPre-clinical
26
EnoxaparineSanofiApproved
43
Alirocumab 150 MG/ML [Praluent]Regeneron PharmaceuticalsPhase 3
36